Adagio Medical (ADGM) Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/17/2026
- Wall St futures fall as chip selloff gathers pace; Netflix tumbles
- Netflix earnings forecast disappoints Wall Street, shares tumble
- Alphabet stock falls on report of Gemini AI model delays
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil settles lower, but remains near one-month high on U.S.-Iran tension
- Nike out of World Cup contention as Adidas-outfitted teams head to final
- Wall Street ends lower as chip weakness offsets solid earnings, economic data
- FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
- Personalis (PSNL) explores potential sale after interest from Merck and others - source
- Intuitive Surgical (ISRG) Tops Q2 EPS by 29c, Beats on Revenue
Adagio Medical Provides Business Updates
August 19, 2024 4:01 PM EDTLAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the Company), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today provided a business update.
Recent Business Highlights:
Obtained CE Mark approval and initiated commercial launch of the vCLAS catheter and ultra-low temperature cryoablation (ULTC) system for treatment of ventricular tachycardia (VT) into select European markets Presented CRYOCURE-VT trial data at European Heart Rhythm Association and Heart Rhythm Society annual meetings with results published in EP Europace journal Obtained the U.S. Food and Drug... More